Arcus Biosciences, Inc. (RCUS)
Market Cap | 1.33B |
Revenue (ttm) | 237.00M |
Net Income (ttm) | -231.00M |
Shares Out | 90.95M |
EPS (ttm) | -3.11 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 709,587 |
Open | 15.32 |
Previous Close | 15.30 |
Day's Range | 14.25 - 15.34 |
52-Week Range | 12.95 - 25.47 |
Beta | 0.85 |
Analysts | Strong Buy |
Price Target | 41.40 (+182.59%) |
Earnings Date | Aug 5, 2024 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclust... [Read more]
Financial Performance
In 2023, RCUS's revenue was $117.00 million, an increase of 4.46% compared to the previous year's $112.00 million. Losses were -$307.00 million, 15.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is $41.4, which is an increase of 182.59% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/c/7/press17-2496288.jpg)
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
![](https://cdn.snapi.dev/images/v1/n/x/press3-2470967.jpg)
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
![](https://cdn.snapi.dev/images/v1/r/p/conf2-2467257.jpg)
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/s/e/press15-2457929.jpg)
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 stud...
![](https://cdn.snapi.dev/images/v1/z/0/press8-2457473.jpg)
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A...
![](https://cdn.snapi.dev/images/v1/r/q/press11-2421695.jpg)
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
![](https://cdn.snapi.dev/images/v1/e/x/press3-2407563.jpg)
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/y/e/conf4-2389259.jpg)
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
![](https://cdn.snapi.dev/images/v1/s/k/conf11-2386608.jpg)
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/s/p/conf16-2299534.jpg)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/p/v/press9-2286982.jpg)
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
![](https://cdn.snapi.dev/images/v1/k/a/conf4-2265798.jpg)
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/a/4/hjuekzkim5pdpaihxwqtct5iuy-2249816.jpg)
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%
Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer ...
![](https://cdn.snapi.dev/images/v1/1/q/press9-2249701.jpg)
Gilead and Arcus Announce Amended Collaboration and Equity Investment
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and ...
![](https://cdn.snapi.dev/images/v1/h/r/press4-2231600.jpg)
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. ARC-...
![](https://cdn.snapi.dev/images/v1/a/6/im-09753645size1777777777777778width800-2208256.jpg)
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
![](https://cdn.snapi.dev/images/v1/1/2/press13-2181736.jpg)
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
ALAMEDA, Calif. and HAYWARD, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration...
![](https://cdn.snapi.dev/images/v1/w/m/press11-2157913.jpg)
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/j/4/press18-2145117.jpg)
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
![](https://cdn.snapi.dev/images/v1/a/n/press10-2142760.jpg)
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemother...
![](https://cdn.snapi.dev/images/v1/6/m/press9-2142759.jpg)
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemothera...
![](https://cdn.snapi.dev/images/v1/z/x/conf4-2107521.jpg)
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of Cl...
![](https://cdn.snapi.dev/images/v1/k/k/conf8-2034199.jpg)
Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people ...
![](https://cdn.snapi.dev/images/v1/r/c/biotech32-2034070.jpg)
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data
Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,...
![](https://cdn.snapi.dev/images/v1/b/1/press20-2009568.jpg)
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...